Shares of Ocuphire are down 31% or $1.15 per share to $2.61 in after-market trading after reporting ZETA-1 Phase 2 trial evaluating oral APX3330 for the treatment of diabetic retinopathy or DR did not meet the primary endpoint.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OCUP:
- OCUP Tanks as Clinical Data Disappoints
- Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
- Ocuphire Pharma enrolls first patient in VEGA-2 Phase 3 trial of Nyxol
- Analysts See Extravagant Gains for These 2 ‘Strong Buy’ Penny Stocks
- Ocuphire Pharma submits NDA to FDA for Nyxol
